Biochemical and electrocardiographic studies on the beneficial effects of gallic acid in cyclophosphamide-induced cardiorenal dysfunction.
Background Cardiac toxicity is one of the life-threatening complications of cancer therapy. Cyclophosphamide (CYP) is an alkylating agent with potent antineoplastic and immunosuppressive properties and possibly the most widely used antineoplastic agent. Chronic cardiotoxicity associated with CYP is characterized by progressive heart failure developing from weeks to years after therapy. Methods In this study, rats were administered with (60 mg/kg and 120 mg/kg) alone or in combination with single intraperitoneal (200 mg/kg) administration of CYP for 7 days. CYP was only administered on day 1. Results The administration of CYP led to a significant (p<0.05) increase in cardiac and renal malondialdehyde (MDA) contents and hydrogen peroxide (H2O2) generation. Also, the activities of catalase (CAT), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and reduced glutathione (GSH) levels were significantly (p<0.05) reduced following CYP treatment. A significant (p<0.05) increase in serum myeloperoxidase (MPO) activity was recorded in rats administered CYP only. Electrocardiogram (ECG) showed a significant (p<0.05) increase in heart rate (HR) accompanied by transient decrease in QRS duration. Histologic examination revealed architectural anarchy of both heart and kidney of rats that received only CYP. Conclusions In this study, treatment with gallic acid (60 mg/kg and 120 mg/kg) restored the enzymic and non-enzymic antioxidants and also attenuated cardiotoxic and nephrotoxic effect of CYP through free radical scavenging activity, anti-inflammatory and improvement of antioxidant defence system.
.
Omolola Rachel
OR
Ogunsanwo
.
Ademola Adetokunbo
AA
Oyagbemi
.
Temidayo Olutayo
TO
Omobowale
.
Ebunoluwa Racheal
ER
Asenuga
.
Adebowale Bernard
AB
Saba
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000975:Antioxidants / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D059347:Cardio-Renal Syndrome / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism / Q000517:prevention & control*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004562:Electrocardiography; D005707:Gallic Acid / Q000627:therapeutic use*; D018384:Oxidative Stress; D020011:Protective Agents / Q000627:therapeutic use*; D051381:Rats; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000975:Antioxidants; D015415:Biomarkers; D020011:Protective Agents; D005707:Gallic Acid; D003520:Cyclophosphamide
cardiotoxicity; chemoprevention; cyclophosphamide; electrocardiogram; nephrotoxicity; oxidative stress